This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
The Current State of Play in Connected Devices
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation, Product Solutions
Exploring a Faster, More Cost-Effective Alternative to Generic Bioequivalence
Publications, Pharmaceutical, Innovation & Insights, Product Solutions
New Tools to Advance CNS Drug Delivery
Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Drug Delivery Innovations
Aptar Pharma discusses challenges and benefits of drug repurposing
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions
